Clinical Trials Logo

Recurrent Prostate Cancer clinical trials

View clinical trials related to Recurrent Prostate Cancer.

Filter by:

NCT ID: NCT06096870 Not yet recruiting - Prostate Cancer Clinical Trials

Enzalutamide and M9241 in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy

Start date: March 31, 2024
Phase: Phase 2
Study type: Interventional

Background: Prostate cancer may return after treatment in 30,000 to 50,000 people each year. There is no clear best way to treat these people. Better treatments are needed. Objective: To test a study drug (enzalutamide), both alone and combined with a second drug (M9241), in people with prostate cancer that returned after treatment. Eligibility: People aged 18 years and older with prostate cancer that returned after treatment. Design: Participants will be screened. They will have a physical exam, with blood tests. All their urine will be collected for 24 hours. They will have imaging scans of their chest, abdomen, pelvis, and bones. Their ability to perform everyday activities will be assessed. They may opt to give a stool sample. Participants will be treated in 4-week cycles. Enzalutamide is a pill taken by mouth once a day, every day. All participants will be given a supply of this drug to take at home. M9241 is injected under the skin once a month, on the first day of each cycle. Half of the participants will receive both drugs. All participants will visit the clinic once a month. Each visit should last no more than 8 hours. Blood and urine tests will be repeated. All participants will receive the study treatment for 3 cycles. Some participants may need 3 more cycles of treatment with enzalutamide only. This re-treatment can be done only once. Participants will have a follow-up visit 1 month after they finish treatment. After that, they will have visits every 6 weeks for up to 5 years. Imaging scans and blood tests will be repeated. ...

NCT ID: NCT06070272 Not yet recruiting - Clinical trials for Recurrent Prostate Cancer

Determining Patterns In Trial Experiences of Recurrent Prostate Cancer Patients

Start date: October 2024
Phase:
Study type: Observational

Clinical studies, with a dedicated focus on recurrent prostate cancer, play a pivotal role in evaluating the safety and effectiveness of novel treatments for this condition. These trials serve as essential tools to determine whether new medications outperform traditional therapies, providing substantial evidence to endorse their broader utilization. It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future patients with recurrent prostate cancer.

NCT ID: NCT05746806 Recruiting - Clinical trials for Recurrent Prostate Cancer

Trial of Ultrahypofractionated Focal Salvage Radiotherapy for Isolated Prostate Bed Recurrence After Radical Prostatectomy

HypoFocal SRT
Start date: March 29, 2023
Phase: N/A
Study type: Interventional

The main objective of the trial is to explore the efficacy and safety of combining short-term androgen deprivation therapy (ADT) over 6 months to focal ultrahypofractionated salvage radiotherapy (SRT) delivered in 5 fractions to the site of local recurrence within the prostate bed after radical prostatectomy where multiparametric magnetic resonance imaging (mpMRI) and prostate-specific membrane antigen (PSMA) PET/CT are used to precisely identify the local recurrence and compare it to previously published literature.

NCT ID: NCT05304858 Recruiting - Clinical trials for Recurrent Prostate Cancer

Tumor Microenvironment Analysis of Prostate Cancer Metastasis

Start date: September 15, 2021
Phase:
Study type: Observational

The purpose of this study is to collect prostate cancer tissue from males with metastatic prostate cancers in order to study the tumor microenvironment (TME), which is the area surrounding the tumor including cells, blood vessels, etc., in men with metastatic prostate cancer. The type of research performed on these tissue samples include genetic & molecular analyses.

NCT ID: NCT05077098 Recruiting - Clinical trials for Recurrent Prostate Cancer

Study of ADXS-504 Immunotherapy for Recurrent Prostate Cancer

Start date: August 12, 2021
Phase: Phase 1
Study type: Interventional

Primary Objective: - To evaluate the safety and tolerability of ADXS-504 and to determine the MTD (maximum tolerated dose) or RP2D (recommended phase two dose) Secondary Objectives: - To characterize the immunological activity of ADXS-504, administered as; and to characterize the genomic profiles of study subjects - To evaluate the effects of ADXS-504 on change in PSA - To evaluate time to PSA progression

NCT ID: NCT05044754 Recruiting - Clinical trials for Recurrent Prostate Cancer

SCAP vs HIFU for Recurrent Prostate Cancer After Radiation Therapy

SALVPROST
Start date: October 1, 2021
Phase:
Study type: Observational [Patient Registry]

The evidence base relating to the use of SCAP and HIFU is poor, with significant uncertainties relating to long-term oncological outcomes. One of the main limitations when the few studies reported are analyzed is the lack of information about the histopathology both before starting treatment and at the time of recurrence after cryotherapy. The vast majority of studies refer only to BCR-free survival as end point, thus limiting interpretation of real oncological performance of this technique. Furthermore, side effects vary widely from study to study and there are uncertainties about the real morbidity associated to cryotherapy in the salvage setting. Another important hot issue in this scenario is the potential benefit that new imaging and diagnosis techniques (MRI, targeted biopsy, PSMA) may add for a more accurate indication. This could provide the possibility of better results for SCAP. The clinical value of this new diagnostic tools is unknown in this scenario and needs to be explored.

NCT ID: NCT04891536 Recruiting - Prostate Cancer Clinical Trials

Salvage Cryotherapy for Recurrent Prostate Cancer After Radiation Therapy

CRIOAND2021
Start date: May 1, 2021
Phase: N/A
Study type: Interventional

The main objective of this project is to establish a shared comprehensive and systematic protocol for a multicenter prospective registry of patients undergoing salvage cryoablation of the prostate (SCAP). Our study hypothesis is that SCAP constitutes an effective and safe approach to treat local prostate cancer recurrence after brachytherapy or external beam radiation therapy (EBRT).

NCT ID: NCT04787744 Recruiting - Prostate Cancer Clinical Trials

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

VA STARPORT
Start date: July 1, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival (CRPC-free survival) for Veterans with oligometastatic prostate cancer. Oligometastasis will be defined as 1-10 sites of metastatic disease based on the clinical determination of the LSI which incorporates all imaging, clinical, and pathologic data available.

NCT ID: NCT04644822 Completed - Clinical trials for Recurrent Prostate Cancer

Safety and Efficacy of [18F]PSMA-1007 Injection in Suspected Persistent or Recurrent Prostate Cancer.

Start date: December 21, 2020
Phase: Phase 3
Study type: Interventional

This is a prospective, Phase 3 non-randomized, open label, multi-centre clinical trial to assess the safety and efficacy of [18F]PSMA-1007 Injection (investigational product or IP) in evaluating men with suspected persistent or recurrent disease (i.e., with biochemical failure), but with negative or equivocal conventional re-staging imaging (bone scan [BS] and computed tomography [CT] of abdomen and pelvis).

NCT ID: NCT04026230 Recruiting - Clinical trials for Metastatic Prostate Cancer

Impact of Atorvastatin on Prostate Cancer Progression During ADT

ESTO2
Start date: August 15, 2019
Phase: Phase 3
Study type: Interventional

This randomized double-blind placebo-controlled trial tests whether intervention with atorvastatin delays development of castration resistance compared to placebo during androgen deprivation therapy (ADT) for prostate cancer.